The Vaccine Conundrum
COVID19 - CORONAVIRUS, 15 Mar 2021
How effective, and safe, are covid vaccines really?
8 Mar 2021 – Initial data from Israel and Scotland appeared to indicate a very high real-world vaccine effectiveness, even in senior citizens. However, much of this data was heavily adjusted for various factors and therefore somewhat tentative and not easy to interpret. Numerous reports of covid outbreaks in care homes even after the second vaccination have raised additional questions.
To clarify this situation, a German study with 176 participants, published last week as a preprint, measured the age-dependent immune response to the Pfizer vaccine. Somewhat shockingly, the study found that one third of people over the age of 80 developed no neutralizing antibodies at all, and thus were potentially without seroprotection even after the second vaccination (see above).
Some of these elderly people developed non-neutralizing antibodies, but their role in Sars-Cov-2 infection remains unknown: they might help reduce symptoms, but they could also increase symptoms (so-called antibody-dependent disease enhancement, ADE). The official vaccine trials included hardly any people of the 80+ age group and so didn’t answer this question.
In vaccine science, a reduced immune response in the elderly is known as immunosenescence.
If the reduced protection in the high-risk group gets confirmed, it may explain the somewhat disappointing performance of many covid vaccination pioneers (such as Israel): in most of these countries, covid hospitalizations and deaths have decreased slower than expected, or have even increased, since the beginning of the mass vaccination campaign (see updated figure below).
Meanwhile, documented post-vaccination deaths continue to rise and are now close to 3000 in the US and the EU. Some of these deaths may be unrelated to vaccinations, but in the US, 47% of post-vaccination deaths occurred in people who became ill within 48 hours of being vaccinated, and 31% of deaths occurred within 48 hours of vaccination. The average age was 78, the youngest case was 23.
Swiss Policy Research, founded in 2016, is an independent, nonpartisan and nonprofit research group investigating geopolitical propaganda in Swiss and international media. SPR is composed of independent academics that for personal and professional reasons prefer to protect their identities, and receives no external funding; there are no financial sponsors or backers. Our articles have been published or shared by numerous independent media outlets and journalists, among them Julian Assange, and have been translated into more than two dozen languages.
Tags: COVID-19, Coronavirus, Vaccines
DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.
Join the discussion!
We welcome debate and dissent, but personal — ad hominem — attacks (on authors, other users or any individual), abuse and defamatory language will not be tolerated. Nor will we tolerate attempts to deliberately disrupt discussions. We aim to maintain an inviting space to focus on intelligent interactions and debates.
Click here to go to the current weekly digest or pick another article:
COVID19 - CORONAVIRUS: